No HBV or HIV co-infection MAGELLAN-I Study : ABT-493 + ABT-530 in genotype 1 with failure to DAA regimen – Phase II Design W12 Randomisation Open-label N = 6 * ABT-493 200 mg qd + ABT-530 80 mg qd SVR12 18-70 years HCV genotype 1 Failure to DAA regimen HCV RNA > 10 000 IU/ml No cirrhosis No HBV or HIV co-infection N = 22 ABT-493 300 mg qd + ABT-530 120 mg qd SVR12 N = 22 ABT-493 300 mg qd + ABT-530 120 mg qd + RBV 800 mg qd SVR12 * Low dose arm halted (based on dose-findings results across all genotypes) Objective SVR12 (HCV RNA < 25 IU/ml), by ITT MAGELLAN-I Poordad F. EASL 2016, Abs. GS11, J Hepatol 2016; 64:S160-1 1

Baseline characteristics MAGELLAN-I Study : ABT-493 + ABT-530 in genotype 1 with failure to DAA regimen – Phase II Baseline characteristics ABT-493 200 mg + ABT-530 80 mg N = 6 ABT-493 300 mg + ABT-530 120 mg N = 22 ABT-493 300 mg + ABT-530 120 mg + RBV 800 mg Median age, years 59 56 Female, % 50 18 Race : White , % 67 55 77 Median BMI, kg/m2 27 28 Genotype 1a, % 82 91 Median HCV RNA, log10 IU/ml 6.1 6.6 6.7 Fibrosis stage (%) : F0-F1 / F2 / F3 67 / 17 / 17 50 / 27 / 23 77 / 0 / 23 Prior regimen PI-experienced, NS5A naïve, n = 25 NS5A-experienced, PI-naïve, n = 8 PI and NS5A-experienced, n = 17 SOF-experienced, n = 16 MAGELLAN-I Poordad F. EASL 2016, Abs. GS11, J Hepatol 2016; 64:S160-1 2

MAGELLAN-I Study : ABT-493 + ABT-530 in genotype 1 with failure to DAA regimen – Phase II SVR12, ITT 6 22 % 100 86 91 N= Breakthrough 1 Relapse Lost to follow-up 2 MAGELLAN-I Poordad F. EASL 2016, Abs. GS11, J Hepatol 2016; 64:S160-1 3

MAGELLAN-I Study : ABT-493 + ABT-530 in genotype 1 with failure to DAA regimen – Phase II 2 virologic failures Prior DAA regimen(s) Response NS3 RAVs NS5A RVAs Baseline Failure OBV/PTV/r + DSV + RBV Breakthrough Y56H D168A/T V36M D168A M28V Q30L/R M28G Q30S DCV ; TVR + PR Relapse None Pending L31M H58D SVR12 (ITTm) according to baseline RAVs No RAVs N = 6 NS3 RAVs only N = 15 NS5A RAVs only N = 10 NS3 & NS5A RAVs N = 16 SVR12 100% 90% 94% MAGELLAN-I Poordad F. EASL 2016, Abs. GS11, J Hepatol 2016; 64:S160-1 4

Adverse events and laboratory abnormalities, % MAGELLAN-I Study : ABT-493 + ABT-530 in genotype 1 with failure to DAA regimen – Phase II Adverse events and laboratory abnormalities, % ABT-493 200 mg + ABT-530 80 mg N = 6 ABT-493 300 mg + ABT-530 120 mg N = 22 ABT-493 300 mg + ABT-530 120 mg + RBV 800 mg Any adverse event 83 77 71 Treatment-related serious adverse event Adverse event leading to discontinuation Adverse events in > 10% of patients Headache Fatigue Nausea Insomnia 17 36 18 14 23 27 Laboratory abnormalities, n ALT grade ≥ 2 / AST grade ≥ 2 Total bilirubin grade 2 Alkaline phosphatase grade ≥ 2 Hemoglobin grade ≥ 2 3 MAGELLAN-I Poordad F. EASL 2016, Abs. GS11, J Hepatol 2016; 64:S160-1 5

MAGELLAN-I Study : ABT-493 + ABT-530 in genotype 1 with failure to DAA regimen – Phase II Summary High SVR12 rates after 12 weeks of ABT-493 + ABT-530 with only 2 virologic failures in 50 DAA-experienced genotype 1 patients without cirrhosis Baseline NS3 and/or NS5A RAVs did not impact SVR12 RBV did not increase SVR12 rate Good tolerability, with mild adverse events No grade 3 or 4 laboratory abnormalities No discontinuation due to adverse events MAGELLAN-I Poordad F. EASL 2016, Abs. GS11, J Hepatol 2016; 64:S160-1 6